CD200: A Potential Drug Target for Cancer Treatment (G4345)
CD200: A Potential Drug Target for Cancer Treatment
CD200 (OX-2 membrane glycoprotein (isoform a)) is a protein that is expressed in a variety of tissues throughout the body, including the brain, spleen, heart, kidneys, and gastrointestinal tract. It is a member of the CD200 family, which includes several related proteins that are involved in the immune response.
CD200 is a glycoprotein, which means that it consists of a protein that is made up of several polypeptide chains. These chains are held together by disulfide bonds, and the overall structure of the protein is determined by the arrangement of these chains. The CD200 protein is made up of a variable region, which consists of the variable region A, B, and C, and a constant region, which consists of the constant region D.
CD200 is a cell surface antigen, which means that it is expressed in the surface of cells and is accessible to the immune system. It is also a potent immune evasive protein, which allows cells to evade the immune response and maintain a state of immune tolerance. This is important for the survival of cancer cells, which often evade the immune response by avoiding expression of antigens on their surfaces.
CD200 is involved in several different processes in the immune system. It is a receptor for antigens, which allows it to interact with immune cells and trigger an immune response. It is also involved in the regulation of inflammation, as it has been shown to play a role in the regulation of tissue inflammation.
CD200 is also a potential drug target. Several studies have suggested that CD200 may be a promising target for cancer treatment, particularly for lung cancer. One study published in the journal Nature Medicine used a small molecule inhibitor to block the activity of CD200 and showed that it was able to inhibit the growth of cancer cells in a variety of models.
Another study published in the journal Cancer Research used a monoclonal antibody to target CD200 and showed that it was able to inhibit the growth of cancer cells in a variety of models. The authors suggested that CD200 may be a promising target for cancer treatment because it is expressed in many different tissues and is not dependent on the specific type of cancer.
CD200 may also be a biomarker for cancer diagnosis and treatment. Several studies have shown that CD200 levels are elevated in a variety of cancer types, which suggests that they may be a useful biomarker for cancer diagnosis and treatment. For example, one study published in the journal Oncology Reports found that CD200 levels were elevated in lung cancer and were correlated with the overall survival of patients.
In conclusion, CD200 is a protein that is expressed in a variety of tissues throughout the body and is involved in several different processes in the immune system. It is a potential drug target and biomarker for cancer treatment, and further research is needed to fully understand its role in the immune system and its potential as a therapeutic target.
Protein Name: CD200 Molecule
Functions: Costimulates T-cell proliferation. May regulate myeloid cell activity in a variety of tissues
The "CD200 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD200 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37
